Buy PE-22-28 Canada | Spadin Peptide
Janoshik
Batch PE22-CA-26F-01
Buy PE-22-28 Canada | Spadin Peptide
TREK-1 Channel Blocker
Also known as Shortened spadin analogue (sortilin propeptide 22–28)
This product is intended strictly for laboratory research use within Canada. It is not approved by Health Canada for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable Canadian regulations.
PE 22-28 is a seven-residue peptide derived from spadin, itself a fragment of the sortilin (NTSR3) propeptide, studied in research as a blocker of the TREK-1 potassium channel.
It was designed from the blood-degradation products of spadin to improve stability while retaining channel activity in experimental models.
PE 22-28 corresponds to residues 22–28 of the sortilin propeptide — the seven-residue core of spadin (PE 12-28). In patch-clamp work on hTREK-1/HEK cells it inhibited the TREK-1 channel with substantially greater potency than spadin itself, and its action persisted markedly longer in vivo.
Research frameworks use it to probe the TREK-1 channel as a target in mood-regulation models, alongside endpoints in neurogenesis and synaptogenesis.
TREK-1 knockout work first identified the background potassium channel as relevant to depression-related phenotypes in mice. That finding motivated a search for endogenous TREK-1 blockers, which led to the description of spadin, a peptide released from the sortilin propeptide.
Because spadin activity in vivo faded within hours, its degradation products were screened for a more stable fragment. The resulting seven-amino-acid peptide, PE 22-28, showed better channel specificity and affinity and a longer duration of action in the reported behavioral models.
Laboratory investigations into PE 22-28 focus on TREK-1 channel inhibition and its behavioral correlates. Research frameworks evaluate patch-clamp potency against hTREK-1, rodent behavioral models of depression such as forced-swim and novelty-suppressed feeding, hippocampal neurogenesis after short treatment windows, and synaptogenesis measured through PSD-95 expression in cortical neurons.
3 of the 4 areas below are addressed directly by a paper cited on this page.
TREK-1 potassium-channel inhibition models
Addressed on this page by Heurteaux C et al. 2006, Djillani A et al. 2017, Mazella J et al. 2010. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Heurteaux C et al. (2006) — Deletion of the background potassium channel TREK-1 results in a depression-resistant phenotype
- Djillani A et al. (2017) — Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity
- Mazella J et al. (2010) — Spadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: a new concept in the antidepressant drug design
Sortilin/NTSR3 propeptide signaling research
Addressed on this page by Mazella J et al. 2018, Mazella J et al. 2010. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Mazella J et al. (2018) — The Involvement of Sortilin/NTSR3 in Depression as the Progenitor of Spadin and Its Role in the Membrane Expression of TREK-1
- Mazella J et al. (2010) — Spadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: a new concept in the antidepressant drug design
Rodent behavioral models of mood regulation
Addressed on this page by Mazella J et al. 2010. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Mazella J et al. (2010) — Spadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: a new concept in the antidepressant drug design
Neurogenesis and synaptogenesis endpoints
No paper cited on this page reports on neurogenesis, synaptogenesis or endpoints. This heading marks where PE-22-28 is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
The references section of this page cites 4 primary papers published between 2006 and 2018 — a limited but non-trivial record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
Worth noting when weighing that record: roughly 50% of the citations here list Mazella J et al. as lead author. A literature concentrated in one research group has not been independently replicated to the same degree as one drawn from many, and that is a real limitation on how far the findings can be generalised — regardless of how consistent the individual results look.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for PE-22-28, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
PE-22-28 is described across this category in connection with TREK-1 potassium-channel inhibition models, sortilin/NTSR3 propeptide signaling research and rodent behavioral models of mood regulation.
The 4 papers cited on this page, published between 2006 and 2018 (1 in animal models) describe laboratory and animal work. None reports a controlled trial in humans. Findings in cell culture or in a rodent model describe what happened in that system; they do not establish that the same occurs in humans, and this compound is not approved for human use.
Presented as having independent scientific backing.
Around 50% of the papers cited here list Mazella J et al. as lead author. A literature concentrated in one research group has not been independently replicated to the degree its volume suggests, and that is a real limit on how far the findings generalise — however consistent the individual results appear.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
Verification for PE-22-28 is per lot, not per product. The current 10mg lot PE22-CA-26F-01 returned 99.754% purity, 12.86 mg measured, 128.6% of the labelled 10 mg, assayed by Janoshik. Those figures are the laboratory's, published in full rather than reduced to a badge.
Purity is half the number. It states what fraction of the material in the vial is PE-22-28; it says nothing about how much material is in the vial, and a short-filled vial can return a purity result that is entirely accurate. The figure that answers the second question is measured mass against expected content — for PE-22-28, this lot measured 128.6% of its labelled 10 mg. Both numbers are published for every lot, whichever way they fall.
The lot code printed on the vial matches the code on the certificate for PE-22-28. Matching the two is what confirms the unit in hand came from the batch that was tested — a certificate not tied to a lot code proves nothing about any particular unit.
Researchers who buy PE-22-28 in Canada through Eppix Labs receive the lot described by the certificate above: the code printed on the vial label is the code on the certificate, and both are searchable on the batch verification page.
- Lyophilized storage
- −20 °C long-term; stable at room temperature in transit
- After reconstitution
- 2–8 °C
- Light
- Protect from UV and direct light
- Freeze-thaw
- Avoid repeated cycles
- Vehicle
- Bacteriostatic water in most published protocols
- Format
- Lyophilized powder
PE-22-28 is supplied as lyophilized powder. In the dry state the material is comparatively stable, which is why it ships at ambient temperature without a cold chain; once reconstituted it is a peptide in solution and the handling constraints tighten considerably. At 7 residues it is short enough to be produced by solid-phase synthesis, and the published sequence on this page is what an identity assay is checked against.
Repeated freeze-thaw cycling is the handling error most likely to degrade material of this class, because each cycle concentrates solutes at the ice boundary. Where a protocol calls for the same vial across multiple sessions, the published literature generally describes aliquoting after reconstitution rather than re-freezing the whole volume.
Vials may appear empty on arrival. Lyophilized material collects at the base of the vial and is often not visible until the vial is inspected under direct light.
- 1 × sealed glass vial in the strength selected (10mg / Single Vial, 10mg / 5-Pack, 10mg / 10-Pack available), batch-labelled
- The batch-linked Certificate of Analysis for the exact lot shipped
- Discreet outer packaging with no product names on the exterior
- Canada Post Xpress, tracked, typically 1–2 business days from Alberta
- Bacteriostatic water or any other reconstitution vehicle
- Syringes, needles or filters
- Dosing, administration or protocol guidance of any kind
Reconstitution materials are sourced separately. The reconstitution calculator on this site works out concentrations for a given volume, but it is an arithmetic tool for laboratory record-keeping and not a protocol.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each unit contains the labeled quantity of PE 22-28. Independent third-party analysis verifies purity, identity, and net content per batch.
The unit contains only the research compound. Any laboratory materials required for reconstitution or experimental procedures must be sourced separately.
Duration depends entirely on research design, storage conditions, and laboratory protocol.
Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity
PubMedSpadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: a new concept in the antidepressant drug design
PubMedThe Involvement of Sortilin/NTSR3 in Depression as the Progenitor of Spadin and Its Role in the Membrane Expression of TREK-1
PubMedDeletion of the background potassium channel TREK-1 results in a depression-resistant phenotype
PubMedRelated
You May Also Like
Next-generation GLP receptor agonist studied for metabolic signaling and nutrient partitioning pathways
$60.00
$70.00
Dual incretin receptor agonist studied for glucose regulation, metabolic signaling, and weight pathway research
$35.00
$40.00
Studied in metabolic research for its effects on glucose regulation, appetite signaling, and energy balance.
From$70.00
This product is supplied as eloralintide (LY3841136), a long-acting, selective amylin receptor agonist studied in research on metabolic and body-weight regulation.
$150.00